A Phase III Randomized, Placebo-Controlled, Clinical Trial to Study the
Safety and Efficacy of V212 in Adult Patients with Solid Tumor or Hematologic
||Anupama Goel, MD
| Time frame of study:
|Location of Study:
Mount Sinai Beth Israel
St.Luke's-Mount Sinai West
Continuum Cancer Research Program
This research study aims to test an investigational vaccine (V212), a
varicella-zoster virus (VZV) vaccine in the prevention of shingles in
subjects with solid tumor malignancy or hematologic tumor malignancy.
This vaccine has been treated with a low dose of radiation to kill the
vaccine virus. The inactivated VZV vaccine is made with one additional
step that stops the virus’ ability to spread. It is possible that
a very small number of virus particles may still be able to spread, and
the inactivated VZV vaccine may contain a little bit of live vaccine virus.
• 18 years of age or older
• Diagnosed with a solid tumor or hematologic malignancy
• Prior history of varicella or antibodies to VZV
• All female patients of childbearing potential must have a negative
serum or urine pregnancy test.
Please call for more information.